FdaApplication
NDA 022426
Identifiers
- fda_app_no: NDA022426
Properties
| Property | Value |
|---|---|
| applicant_name | TAKEDA PHARMACEUTICALS USA INC |
| application_type | NDA |
| approval_date | 2013-01-25 |
Products (6)
| Product | Active ingredient | Strength | Dosage form |
|---|---|---|---|
| OSENI | ALOGLIPTIN BENZOATE; PIOGLITAZONE HYDROCHLORIDE | EQ 12.5MG BASE;EQ 30MG BASE | TABLET;ORAL |
| OSENI | ALOGLIPTIN BENZOATE; PIOGLITAZONE HYDROCHLORIDE | EQ 12.5MG BASE;EQ 45MG BASE **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** | TABLET;ORAL |
| OSENI | ALOGLIPTIN BENZOATE; PIOGLITAZONE HYDROCHLORIDE | EQ 12.5MG BASE;EQ 15MG BASE **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** | TABLET;ORAL |
| OSENI | ALOGLIPTIN BENZOATE; PIOGLITAZONE HYDROCHLORIDE | EQ 25MG BASE;EQ 15MG BASE | TABLET;ORAL |
| OSENI | ALOGLIPTIN BENZOATE; PIOGLITAZONE HYDROCHLORIDE | EQ 25MG BASE;EQ 45MG BASE | TABLET;ORAL |
| OSENI | ALOGLIPTIN BENZOATE; PIOGLITAZONE HYDROCHLORIDE | EQ 25MG BASE;EQ 30MG BASE | TABLET;ORAL |
6 products